3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Endocrine
1
Conditions
Gastrointestinal Stromal Tumors
31
Colorectal Neoplasms
12
Pancreatic Neoplasms
11
Carcinoma, Hepatocellular
11
Stomach Neoplasms
8
Neoplasms
7
Liver Neoplasms
7
Esophageal Neoplasms
6
Carcinoma, Renal Cell
6
Neoplasm Metastasis
5
Gastrointestinal Neoplasms
5
Adenoma, Islet Cell
5
Neuroendocrine Tumors
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Carcinoma
3
Thyroid Neoplasms
2
Sarcoma
2
Rectal Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Multiple Myeloma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Digestive System Neoplasms
2
Colonic Neoplasms
2
Adenoma
2
Adenocarcinoma Of Esophagus
2
Interventions
Gemcitabine
4
pembrolizumab
3
napabucasin
3
Irinotecan
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
lenvatinib
2
entinostat
2
Taxes
2
Sunitinib
2
Sorafenib
2
Paclitaxel
2
Leucovorin
2
Fluorouracil
2
Cisplatin
2
Bevacizumab
2
pralsetinib
1
linifanib
1
durvalumab
1
Radiofrequency Ablation
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Endoscopic Mucosal Resection
1
Cobicistat
1
Chemoradiotherapy
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
Sunitinib
×
Gastrointestinal
×
Clear all
NCT01215578
2015-04-30
NET
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
33 enrolled
NCT01215565
2014-03-13
Fibrolam
Assistance Publique - Hôpitaux de Paris
Phase 2
Terminated
4 enrolled